First Discussion Opportunity for EC Pharmaceutical Package
A New Vision for the Pharmaceutical Sector-First Discussion Opportunity for European Commission Pharmaceutical Package
Brussels- The first in-depth opportunity to understand, debate and influence new European Commission (EC) legislative changes and their implications-the Proposals for new Pharmaceutical Legislation EU update meeting-is being hosted by The Organisation for Professionals in Regulatory Affairs (TOPRA) on 25-26 February 2009.
Over the two days of this meeting nearly 20 speakers from the European Commission, pan-European national agencies, national authorities and industry will discuss the European Pharmaceutical Package announced by the European Commission on 10th December 2008 and give their view on the new legislation proposals.
Issues discussed at the conference will include the development, purpose and expected outcomes of the pharmaceutical package, counterfeit medicines, information to patients and pharmacovigilance. Please find
attached the draft programme which gives further detail.
This conference has relevance for all of industry, health agencies and other stakeholders. It should be attended by anyone that the 'Pharma Package' will affect.
The organisers would like to take this opportunity to invite you to conference and take advantage of a number of free press passes that are available.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
